Mark Avagliano - 03 Jan 2023 Form 4 Insider Report for G1 Therapeutics, Inc.

Role
Chief Business Officer
Signature
/s/ James Stillman Hanson, attorney-in-fact
Issuer symbol
N/A
Transactions as of
03 Jan 2023
Net transactions value
$0
Form type
4
Filing time
05 Jan 2023, 19:25:44 UTC
Previous filing
05 Jan 2022
Next filing
12 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GTHX Common Stock Award $0 +20,600 +96% $0.000000 42,155 03 Jan 2023 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GTHX Stock Options (Right to buy) Award $0 +41,100 $0.000000 41,100 03 Jan 2023 Common Stock 41,100 $5.73 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a restricted stock unit ("RSU") award that vests 25% on January 3, 2024 and 12.5% semi-annually thereafter, subject to the Reporting Person's continued service through each applicable vesting date.
F2 Each RSU represents a contingent right to receive one share of Issuer common stock.
F3 Represents (i) 7,055 shares of common stock; (ii) 5,500 RSUs from award granted on January 4, 2021; (iii) 9,000 RSUs from award granted on January 3, 2022; and (iv) 20,600 RSUs from award granted on January 3, 2023.
F4 The shares underlying this option vest as to 25% of the shares on January 3, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.

Remarks:

Note: On January 3, 2023, the reporting person was also granted performance-based restricted stock units that are subject to material conditions beyond the reporting person's control, and, therefore, not considered derivative securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, and excluded from this report.